Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
Anticancer Res ; 44(7): 2909-2919, 2024 07.
Article in English | MEDLINE | ID: mdl-38925848

ABSTRACT

BACKGROUND/AIM: NUAK family kinase 2 (NUAK2) is a promising target for cancer therapeutics due to its reported role in protein phosphorylation, a critical process in cancer cell survival, proliferation, invasion, and senescence. This study aimed to identify novel inhibitors that disrupt NUAK2 activity. We have already identified two KRICT Hippo kinase inhibitor (KHKI) compounds, such as KHKI-01128 and KHKI-01215. Our aim was to evaluate the impact of KHKI-01128 and KHKI-01215 on NUAK2 activity and elucidate its mechanism in colorectal cancer cells. MATERIALS AND METHODS: To evaluate anticancer properties of these inhibitors, four in vitro assays in the SW480 cell line (time-resolved fluorescence resonance energy transfer assay, KINOMEscan kinase profiling, viability, and apoptosis assays) and two pharmacological mechanism analyses (Gene Set Enrichment Analysis and western blotting) were performed. RESULTS: KHKI-01128 and KHKI-01215 exhibited potent inhibitory activity against NUAK2 (half-maximal inhibitory concentration=0.024±0.015 µM and 0.052±0.011 µM, respectively). These inhibitors suppressed cell proliferation, with half-maximal inhibitory concentrations of 1.26±0.17 µM and 3.16±0.30 µM, respectively, and induced apoptosis of SW480 cells. Gene Set Enrichment Analysis revealed negative enrichment scores of -0.84 for KHKI-01128 (false-discovery rate=0.70) and 1.37 for KHKI-01215 (false-discovery rate=0.18), indicating that both effectively suppressed the expression of YES1-associated transcriptional regulator (YAP) target genes. CONCLUSION: These results suggest that KHKI-01128 and KHKI-01215 are potent NUAK2 inhibitors with promising potential for pharmaceutical applications.


Subject(s)
Antineoplastic Agents , Apoptosis , Cell Proliferation , Colorectal Neoplasms , Protein Kinase Inhibitors , Protein Serine-Threonine Kinases , Humans , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/pathology , Colorectal Neoplasms/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Apoptosis/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Antineoplastic Agents/pharmacology , Protein Kinase Inhibitors/pharmacology , Transcription Factors/antagonists & inhibitors , Transcription Factors/metabolism , Cell Survival/drug effects , Protein Kinases/metabolism
2.
Cells ; 12(17)2023 08 23.
Article in English | MEDLINE | ID: mdl-37681864

ABSTRACT

Stroke is a major global health problem that causes significant mortality and long-term disability. Post-stroke neurological impairment is a complication that is often underestimated with the risk of persistent neurological deficits. Although traditional Chinese medicines have a long history of being used for stroke, their scientific efficacy remains unclear. Scutellaria baicalensis, an herbal component known for its anti-inflammatory and antioxidant properties, has traditionally been used to treat brain disorders. This study investigated the therapeutic effects of the Scutellaria baicalensis extraction (SB) during the acute stage of ischemic stroke using photothrombotic (PTB)-induced and transient middle cerebral artery occlusion (tMCAO) model mice. We found that SB mitigated ischemic brain injury, as evidenced by a significant reduction in the modified neurological severity score in the acute stage of PTB and both the acute and chronic stages of tMCAO. Furthermore, we elucidated the regulatory role of SB in the necroptosis and pyroptosis pathways during the acute stage of stroke, underscoring its protective effects. Behavioral assessments demonstrated the effectiveness of SB in ameliorating motor dysfunction and cognitive impairment compared to the group receiving the vehicle. Our findings highlight the potential of SB as a promising therapeutic candidate for stroke. SB was found to help modulate the programmed cell death pathways, promote neuroprotection, and facilitate functional recovery.


Subject(s)
Ischemic Stroke , Stroke , Animals , Mice , Ischemic Stroke/drug therapy , Scutellaria baicalensis , Stroke/complications , Stroke/drug therapy , Apoptosis , Pyroptosis
3.
Biomed Pharmacother ; 146: 112350, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34952740

ABSTRACT

This study explored the radioprotective effects and possible underlying mechanisms of KR-31831 against radiation-induced injury in a mouse model. KR-31831 (30 and 50 mg/kg) was administered to mice 24 h and 30 min before exposure to a single lethal or sublethal dose of whole-body irradiation (WBI) (7 or 4 Gy, respectively). These animals were then evaluated for changes in mortality, various hematological and biochemical parameters, and histological features in response to these treatments. In addition, RNA sequencing was used to profile the radiation-induced transcriptomic response in the bone marrow cells. The results showed that KR-31831 dose-dependently prolonged the 30-day survival period and prevented damage to radiation-sensitive organs, such as the intestine and testis, in response to WBI. Damage to the hematopoietic system was also notably improved in the KR-31831-treated mice, as evidenced by an increase in bone marrow and peripheral blood cells, as well as recovery of the histopathological characteristics of the bone marrow. These protective effects were achieved, at least in part, via the suppression of radiation-induced increases in apoptotic cell death and erythropoietin levels in the plasma. Furthermore, the gene expression profiles of the bone marrow cells of the WBI-treated mice suggested that KR-31831 upregulates the expression of the genes involved in regulating apoptosis and modulating the immune response, both of which are required for protecting the bone marrow. These results suggest the potential therapeutic efficacy of KR-31831 for protection against radiation-induced injury.


Subject(s)
Benzopyrans/therapeutic use , Imidazoles/therapeutic use , Radiation Injuries/drug therapy , Radiation-Protective Agents/therapeutic use , Whole-Body Irradiation/adverse effects , Animals , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Bone Marrow Cells/radiation effects , Intestines/drug effects , Intestines/radiation effects , Male , Mice, Inbred C57BL , Radiation Injuries/genetics , Testis/drug effects , Testis/radiation effects , Transcriptome/drug effects
4.
Biomol Ther (Seoul) ; 28(5): 482-489, 2020 Sep 01.
Article in English | MEDLINE | ID: mdl-32856617

ABSTRACT

G protein-coupled receptor kinase 5 (GRK5) has been considered as a potential target for the treatment of heart failure as it has been reported to be an important regulator of pathological cardiac hypertrophy. To discover novel scaffolds that selectively inhibit GRK5, we have identified a novel small molecule inhibitor of GRK5, KR-39038 [7-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl) amino)-2-(2-chlorophenyl)-6-fluoroquinazolin-4(3H)-one]. KR-39038 exhibited potent inhibitory activity (IC50 value=0.02 µM) against GRK5 and significantly inhibited angiotensin II-induced cellular hypertrophy and HDAC5 phosphorylation in neonatal cardiomyocytes. In the pressure overload-induced cardiac hypertrophy mouse model, the daily oral administration of KR-39038 (30 mg/kg) for 14 days showed a 43% reduction in the left ventricular weight. Besides, KR-39038 treatment (10 and 30 mg/kg/ day, p.o.) showed significant preservation of cardiac function and attenuation of myocardial remodeling in a rat model of chronic heart failure following coronary artery ligation. These results suggest that potent GRK5 inhibitor could effectively attenuate both cardiac hypertrophy and dysfunction in experimental heart failure, and KR-39038 may be useful as an effective GRK5 inhibitor for pharmaceutical applications.

5.
Bioorg Med Chem Lett ; 30(2): 126787, 2020 01 15.
Article in English | MEDLINE | ID: mdl-31759849

ABSTRACT

The 11ß-hydroxysteroiddehydrogenase type 1(11ß-HSD1), acortisolregenerating enzyme that amplifies tissue glucocorticoidlevels, plays an important role in diabetes, obesity, and glaucoma and is recognized as a potential therapeutic target for various disease conditions. Moreover, a recent study demonstrated that selective 11ß-HSD1 inhibitor can attenuate ischemic brain injury. This prompted us to optimize cyclic sulfamide derivative for aiming to treat ischemic brain injury. Among the synthesized compounds, 6e has an excellent in vitro activivity with an IC50 value of 1 nM toward human and mouse 11ß-HSD1 and showed good 11ß-HSD1 inhibition in ex vivo study using brain tissue isolated from mice. Furthermore, in the transient middle cerebral artery occlusion model in mice, 6e treatment significantly attenuated infarct volume and neurological deficit following cerebral ischemia/reperfusion injury. Additionally, binding modes of 6e for human and mouse 11ß-HSD1 were suggested.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors , Amides/chemistry , Enzyme Inhibitors/chemistry , 11-beta-Hydroxysteroid Dehydrogenase Type 1/metabolism , Amides/metabolism , Animals , Brain/metabolism , Brain Injuries/drug therapy , Brain Injuries/pathology , Cyclization , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/therapeutic use , Humans , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/pathology , Injections, Intraperitoneal , Mice , Structure-Activity Relationship
6.
Int J Radiat Biol ; 95(8): 1094-1102, 2019 08.
Article in English | MEDLINE | ID: mdl-30831047

ABSTRACT

Purpose: The present study aimed to investigate the potential protective effects of icariin both in vivo and in vitro, an active flavonoid glucoside derived from medicinal herb Epimedium, and its possible mechanisms against radiation-induced injury. Methods: Male C57BL/6 mice were exposed to lethal dose (7 Gy) or sub-lethal dose (4 Gy) of whole body radiation by X-ray at a dose rate of ∼0.55 Gy/min, and icariin was given three times at 24 h and 30 min before and 24 h after the irradiation. After irradiation, hematological, biochemical, and histological evaluations were performed. We further determined the effect of icariin on radiation-induced cytotoxicity and changes in apoptosis-related protein expression. Results: Icariin enhanced the 30-day survival rates (20 and 40 mg/kg) in a dose-dependent manner, and protected the radiosensitive organs such as intestine and testis from the radiation damages. Moreover, hematopoietic damage by radiation was significantly decreased in icariin-treated mice as demonstrated by the increases in number of peripheral blood cells, bone marrow cells (1.7-fold), and spleen colony forming units (1.7-fold). In addition, icariin decreased the radiation-induced oxidative stress by modulating endogenous antioxidant levels. Subsequent in vitro studies showed that icariin effectively increased cell viability (1.4-fold) and suppressed the expression of apoptosis-related proteins after irradiation. Conclusion: These results suggest that icariin has significant protective effects against radiation-induced damages partly through its anti-oxidative and anti-apoptotic properties.


Subject(s)
Flavonoids/pharmacology , Radiation-Protective Agents/pharmacology , Animals , Apoptosis/radiation effects , Hematopoietic System/radiation effects , Humans , K562 Cells , Male , Mice , Mice, Inbred C57BL , Superoxide Dismutase/metabolism , Whole-Body Irradiation
7.
Eur J Pharmacol ; 799: 94-102, 2017 Mar 15.
Article in English | MEDLINE | ID: mdl-28163023

ABSTRACT

Urotensin II and its receptor are thought to be involved in various cardiovascular diseases such as heart failure, pulmonary hypertension and atherosclerosis. Since the regulation of the urotensin II/urotensin II receptor offers a great potential for therapeutic strategies related to the treatment of cardiovascular diseases, the study of selective and potent antagonists for urotensin II receptor is more fascinating. This study was designed to determine the potential therapeutic effects of a newly developed novel urotensin II receptor antagonist, N-(1-(3-bromo-4-(piperidin-4-yloxy)benzyl)piperidin-4-yl)benzo[b]thiophene-3-carboxamide (KR-36996), in experimental models of heart failure. KR-36996 displayed a high binding affinity (Ki=4.44±0.67nM) and selectivity for urotensin II receptor. In cell-based study, KR-36996 significantly inhibited urotensin II-induced stress fiber formation and cellular hypertrophy in H9c2UT cells. In transverse aortic constriction-induced cardiac hypertrophy model in mice, the daily oral administration of KR-36996 (30mg/kg) for 14 days significantly decreased left ventricular weight by 40% (P<0.05). In myocardial infarction-induced chronic heart failure model in rats, repeated echocardiography and hemodynamic measurements demonstrated remarkable improvement of the cardiac performance by KR-36996 treatment (25 and 50mg/kg/day, p.o.) for 12 weeks. Moreover, KR-36996 decreased interstitial fibrosis and cardiomyocyte hypertrophy in the infarct border zone. These results suggest that potent and selective urotensin II receptor antagonist could efficiently attenuate both cardiac hypertrophy and dysfunction in experimental heart failure. KR-36996 may be useful as an effective urotensin II receptor antagonist for pharmaceutical or clinical applications.


Subject(s)
Cardiomegaly/drug therapy , Heart Failure/complications , Heart/drug effects , Heart/physiopathology , Piperidines/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Thiophenes/pharmacology , Animals , Body Weight/drug effects , Cardiomegaly/complications , Cardiomegaly/pathology , Cardiomegaly/physiopathology , Cell Line , Chronic Disease , Electrocardiography , Hemodynamics/drug effects , Humans , Male , Mice , Myocardium/metabolism , Myocardium/pathology , Organ Size/drug effects , Piperidines/metabolism , Piperidines/toxicity , Pressure/adverse effects , Rats , Receptors, G-Protein-Coupled/metabolism , Substrate Specificity , Thiophenes/metabolism , Thiophenes/therapeutic use , Thiophenes/toxicity
8.
Int Immunopharmacol ; 40: 196-202, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27611861

ABSTRACT

The pathophysiological implications of binding of urotensin II (U-II) to urotensin II receptor (UT) in pulmonary arterial hypertension (PAH) have been proposed recently. Besides high expression of U-II in experimental models and patients with PAH, U-II has been shown to increase proliferation of pulmonary vascular smooth muscle cells and inflammatory responses, which were critical for PAH pathophysiology. However, the direct role of the urotensinergic system in the pathogenesis of PAH is yet to be understood. The aim of the present study was to determine whether a novel UT antagonist, KR36676, attenuates the pathophysiological progression of PAH in an animal model of PAH. PAH was induced by a single subcutaneous injection of monocrotaline (MCT, 60mg/kg) in rats. All the animals received KR36676 (30mg/kg/day) or vehicle by oral gavage. Three weeks after MCT-injection, changes in hemodynamic parameters, extent of right ventricular hypertrophy, fibrosis and pulmonary vascular remodeling, and degree of protein expression were determined. Oral administration of KR36676 effectively decreased the MCT-induced increase in right ventricular systolic pressure, hypertrophy and fibrosis. Furthermore, wall thickness of pulmonary arterioles, proliferation of pulmonary vascular cells, and inflammatory response significantly decreased in the KR36676-treated group following MCT injection compared to that in the MCT-treated vehicle group. These preventive effects of KR36676 are mediated, at least in part, by suppression of ERK1/2 and NF-κB signaling pathways. The novel UT antagonist, KR36676, effectively prevented MCT-induced PAH progression and pulmonary vascular remodeling in rat model. Our findings support the therapeutic efficacy of UT antagonist in PAH prevention and elucidate the possible underlying mechanisms of action.


Subject(s)
Acetamides/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Benzoxazines/therapeutic use , Hypertension, Pulmonary/drug therapy , Receptors, G-Protein-Coupled/antagonists & inhibitors , Acetamides/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Benzoxazines/pharmacology , Collagen/metabolism , Heart Ventricles/metabolism , Heart Ventricles/pathology , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/pathology , Hypertrophy, Right Ventricular/chemically induced , Hypertrophy, Right Ventricular/drug therapy , Hypertrophy, Right Ventricular/metabolism , Hypertrophy, Right Ventricular/pathology , MAP Kinase Signaling System/drug effects , Male , Monocrotaline , NF-kappa B/metabolism , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/metabolism , Vascular Remodeling/drug effects
9.
Bioorg Med Chem Lett ; 24(17): 4080-3, 2014 Sep 01.
Article in English | MEDLINE | ID: mdl-25124116

ABSTRACT

Erythropoietin-producing hepatocellular receptor tyrosine kinase subtype A2 (EphA2) is an attractive therapeutic target for suppressing tumor progression. In our efforts to discover novel small molecules to inhibit EphA2, a class of compound based on 4-substituted quinazoline containing 7-(morpholin-2-ylmethoxy) group was identified as a novel hit by high throughput screening campaign. Structural modification of parent quinazoline scaffolds by introducing substituents on aniline displayed potent inhibitory activities toward EphA2.


Subject(s)
Protein Kinase Inhibitors/pharmacology , Quinazolines/pharmacology , Receptor, EphA2/antagonists & inhibitors , Dose-Response Relationship, Drug , Humans , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Quinazolines/chemical synthesis , Quinazolines/chemistry , Receptor, EphA2/metabolism , Structure-Activity Relationship
10.
Bioorg Med Chem Lett ; 23(24): 6711-6, 2013 Dec 15.
Article in English | MEDLINE | ID: mdl-24210504

ABSTRACT

G-protein-coupled receptor kinase (GRK)-2 and -5 are emerging therapeutic targets for the treatment of cardiovascular disease. In our efforts to discover novel small molecules to inhibit GRK-2 and -5, a class of compound based on 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine was identified as a novel hit by high throughput screening campaign. Structural modification of parent benzoxazole scaffolds by introducing substituents on phenyl displayed potent inhibitory activities toward GRK-2 and -5.


Subject(s)
Amines/chemistry , Drug Design , G-Protein-Coupled Receptor Kinase 2/antagonists & inhibitors , G-Protein-Coupled Receptor Kinase 5/antagonists & inhibitors , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Benzoxazoles/chemistry , Binding Sites , Catalytic Domain , Enzyme Activation/drug effects , G-Protein-Coupled Receptor Kinase 2/metabolism , G-Protein-Coupled Receptor Kinase 5/metabolism , Molecular Docking Simulation , Protein Binding , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/metabolism , Pyrazoles/chemistry , Pyridines/chemistry , Structure-Activity Relationship
11.
Eur J Pharmacol ; 702(1-3): 218-26, 2013 Feb 28.
Article in English | MEDLINE | ID: mdl-23376156

ABSTRACT

The arising critical implications of Rho kinase signaling in cardiovascular diseases have been attracting attention in the pharmacological potential of Rho kinase inhibitors. We identified a novel inhibitor of Rho kinase (2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine; DW 1865) and characterized its effects in biochemical, cellular, tissue and animal based assays. DW 1865 potently inhibited the kinase activity of both Rho kinase 1 and Rho kinase 2 in vitro, and behaved as an ATP-competitive inhibitor. Interestingly, DW1865 was 10 times more potent in inhibiting Rho kinase activities than fasudil as a selective Rho kinase inhibitor. The activity of DW1865 was shown to be highly selective for Rho kinase in the panel assay of 13 other kinases. In the isolated vascular tissue study, DW1865 exerted vasorelaxation in phenylephrine- or 5-hydroxytriptamine-induced contraction in a concentration-dependent manner manner. In spontaneously hypertensive rats, administration of DW1865 caused a significant and dose-related reduction in blood pressure. Furthermore, DW1865 blocked angiotensin II-induced stress fiber formation and cellular hypertrophy in rat heart-derived H9c2 cells. Taken together, these results suggest that DW1865 is a highly selective and potent Rho kinase inhibitor that will alleviate the pathophysiological actions of Rho kinase such as stress fiber formation, cellular hypertrophy, and hypertension.


Subject(s)
Antihypertensive Agents/pharmacology , Indazoles/pharmacology , Protein Kinase Inhibitors/pharmacology , Triazines/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Actins/metabolism , Animals , Antihypertensive Agents/therapeutic use , Aorta, Thoracic/drug effects , Aorta, Thoracic/physiology , Cardiac Myosins/metabolism , Cell Line , Hypertension/drug therapy , Hypertension/physiopathology , Indazoles/therapeutic use , Male , Myosin Light Chains/metabolism , Myosin-Light-Chain Phosphatase/metabolism , Protein Kinase Inhibitors/therapeutic use , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Triazines/therapeutic use , Vasodilation/drug effects , rho-Associated Kinases/metabolism
12.
Int Immunopharmacol ; 11(11): 1901-6, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21839184

ABSTRACT

Salvianolic acid A, an active compound present in Salvia miltiorrhiza, is a phenolic carboxylic acid derivative, ((2R)-3-(3,4-Dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl) ethenyl]-3,4-dihydroxyphenyl] prop-2-enoyl]oxypropanoic acid). The present study was performed to investigate the underlying mechanisms of anti-inflammatory effects with salvianolic acid A, specially focused on nuclear factor κB (NF-κB) signaling pathway by targeting the IκB kinase ß (IKKß). The effect of salvianolic acid A for IKKß activity was analyzed using an immobilized metal affinity for phosphochemicals (IMAP)-based time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The underlying mechanisms of salvianolic acid A were examined using lipopolysaccharide (LPS)-stimulated RAW264.7 cells. IKKß studies based on IMAP-TR-FRET showed that salvianolic acid A possesses a potent IKKß inhibitory activity with Ki value of 3.63 µM in an ATP-noncompetitive manner. Pretreatment with salvianolic acid A (10, 30 µM) decreased LPS-induced expression of iNOS and COX-2, thereby inhibiting production of nitric oxide and prostaglandin E(2), respectively. In addition, salvianolic acid A (10, 30 µM) also attenuated the LPS-induced IκBα phosphorylation and degradation, and NF-κB translocation. These results suggest that salvianolic acid A modulates NF-κB-dependent inflammatory pathways through IKKß inhibition and these anti-inflammatory effects will aid in understanding the pharmacology and mode of action of salvianolic acid A.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Caffeic Acids/pharmacokinetics , I-kappa B Kinase/antagonists & inhibitors , Lactates/pharmacokinetics , Lipopolysaccharides/pharmacology , NF-kappa B/metabolism , Animals , Cell Line , Cell Survival/drug effects , Cyclooxygenase 2/metabolism , Dinoprostone/metabolism , Fluorescence Resonance Energy Transfer , Immunoblotting , Macrophages/drug effects , Macrophages/enzymology , Macrophages/metabolism , Mice , Microscopy, Fluorescence , Molecular Structure , Nitric Oxide Synthase Type II/metabolism , Nitrites/metabolism
13.
J Ethnopharmacol ; 134(2): 288-93, 2011 Mar 24.
Article in English | MEDLINE | ID: mdl-21182917

ABSTRACT

AIM OF THE STUDY: The present study was performed to investigate the underlying mechanisms of anti-inflammatory effects with the extract of Euonymus alatus (EEA), and specially focused on nuclear factor κB (NF-κB) signaling pathway by targeting the IκB kinase ß (IKKß). MATERIALS AND METHODS: The effect of EEA for IKKß activity was analyzed using an immobilized metal affinity for phosphochemicals (IMAP)-based time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The effect of EEA on lipopolysaccharide (LPS)-induced NF-κB activation in murine macrophage RAW 264.7 cells with western blotting and immunofluorescent staining was evaluated. RESULTS: IKKß studies based on IMAP-TR-FRET showed that EEA possesses a potent IKKß inhibitory activity with IC(50) value of 11.83µg/ml. EEA (10, 30µg/ml) also attenuated the LPS-induced IκBα phosphorylation/degradation, NF-κB translocation and subsequent NO synthesis in RAW 264.7 cells. CONCLUSIONS: These results suggest that EEA abrogates LPS-induced NF-κB signaling pathway by targeting the IKKß in RAW 264.7 cells and these properties may provide a molecular basis for understanding the inhibitory effects of EEA on LPS-mediated inflammation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Euonymus , I-kappa B Kinase/antagonists & inhibitors , Macrophages/drug effects , NF-kappa B/metabolism , Plant Extracts/pharmacology , Animals , Anti-Inflammatory Agents/therapeutic use , Biological Transport/drug effects , Inflammation/drug therapy , Inhibitory Concentration 50 , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Mice , Nitric Oxide/biosynthesis , Phosphorylation , Phytotherapy , Plant Extracts/therapeutic use , Signal Transduction/drug effects
14.
J Ethnopharmacol ; 122(2): 216-20, 2009 Mar 18.
Article in English | MEDLINE | ID: mdl-19330910

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: In Korea, Morus alba leaves have been traditionally administered as natural therapeutic agent for the alleviating dropsy and diabetes. AIM OF THE STUDY: The present study was performed to evaluate melanin-concentrating hormone receptor subtype 1 (MCH1) antagonism of the ethanol extract of Morus alba leaves (EMA) and its anti-obesity effect in diet-induced obese (DIO) mice. MATERIALS AND METHODS: The binding affinity of EMA for the MCH1 receptor with europium-labeled MCH (Eu-MCH), the function of recombinant MCH1 receptors expressed in CHO cells, and the anti-obesity effects in DIO mice were evaluated. RESULTS: MCH1 receptor binding studies showed, EMA exhibited a potent inhibitory activity with IC50 value of 2.3+/-1.0 microg/ml. EMA (10-100 microg/ml) also inhibited the intracellular calcium mobilization with the recombinant MCH1 receptors expressed in CHO cells. In an anti-obesity study with DIO mice, longterm oral administrations of EMA for 32 consecutive days produced a dose-dependent decrease in body weight and hepatic lipid accumulation. CONCLUSIONS: These results suggest that chronic treatment with EMA exerts an anti-obesity effect in DIO mice, and its direct MCH1 receptor antagonism may contribute to decrease body weight.


Subject(s)
Anti-Obesity Agents/therapeutic use , Morus , Obesity/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Receptors, Pituitary Hormone/antagonists & inhibitors , Adipose Tissue/drug effects , Animals , Anti-Obesity Agents/pharmacokinetics , Anti-Obesity Agents/pharmacology , Body Weight/drug effects , CHO Cells , Calcium/metabolism , Cricetinae , Cricetulus , Cyclobutanes/pharmacology , Cyclobutanes/therapeutic use , Diet , Energy Intake/drug effects , Humans , Lipid Metabolism/drug effects , Liver/drug effects , Mice , Mice, Inbred C57BL , Plant Extracts/pharmacokinetics , Plant Extracts/pharmacology
15.
J Pharmacol Sci ; 109(2): 222-32, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19234365

ABSTRACT

The cardioprotective effects of KR-31761, a newly synthesized K+(ATP) opener, were evaluated in rat models of ischemia/reperfusion (I/R) heart injury. In isolated rat hearts subjected to 30-min global ischemia/30-min reperfusion, KR-31761 perfused prior to ischemia significantly increased both the left ventricular developed pressure (% of predrug LVDP: 17.8, 45.1, 54.2, and 62.6 for the control, 1 microM, 3 microM, and 10 microM, respectively) and double product (DP: heart rate x LVDP; % of predrug DP: 17.5, 44.9, 56.2, and 64.5 for the control, 1 microM, 3 microM, and 10 microM, respectively) at 30-min reperfusion while decreasing the left ventricular end-diastolic pressure (LVEDP). KR-31761 (10 microM) significantly increased the time to contracture during the ischemic period, whereas it concentration-dependently decreased the lactate dehydrogenase release during reperfusion. All these parameters were significantly reversed by 5-hydroxydecanoate (5-HD, 100 microM) and glyburide (1 microM), selective and nonselective blockers of the mitochondrial K+(ATP) (mitoK+(ATP)) channel and K+(ATP) channel, respectively. In anesthetized rats subjected to 30-min occlusion of left anterior descending coronary artery/2.5-h reperfusion, KR-31761 administered 15 min before the onset of ischemia significantly decreased the infarct size (72.2%, 55.1%, and 47.1% for the control, 0.3 mg/kg, i.v., and 1.0 mg/kg, i.v., respectively); and these effects were completely and almost completely abolished by 5-HD (10 mg/kg, i.v.) and HMR-1098, a selective blocker of sarcolemmal K+(ATP) (sarcK+(ATP)) channel (6 mg/kg, i.v.) administered 5 min prior to KR-31761 (72.3% and 67.9%, respectively). KR-31761 only slightly relaxed methoxamine-precontracted rat aorta (IC50: > 30.0 microM). These results suggest that KR-31761 exerts potent cardioprotective effects through the opening of both mitoK+(ATP) and sarcK+(ATP) channels in rat hearts with a minimal vasorelaxant effect.


Subject(s)
Benzopyrans/therapeutic use , Cardiotonic Agents/therapeutic use , Indoles/therapeutic use , KATP Channels/agonists , Potassium Channels/agonists , Reperfusion Injury/drug therapy , Animals , Disease Models, Animal , In Vitro Techniques , Male , Mitochondria, Heart/drug effects , Rats , Rats, Sprague-Dawley , Sarcolemma/drug effects , Vasodilation/drug effects
16.
J Pharmacol Exp Ther ; 328(1): 10-8, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18836068

ABSTRACT

Blocking of poly(ADP-ribose) polymerase (PARP)-1 has been expected to protect the heart from ischemia-reperfusion injury. We have recently identified a novel and orally active PARP-1 inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl)-methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], and its major metabolite, KR-34285 [2-[carboxy(4-methoxyphenyl)methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide]. KR-33889 potently inhibited PARP-1 activity with an IC(50) value of 0.52 +/- 0.10 microM. In H9c2 myocardial cells, KR-33889 (0.03-30 microM) showed a resistance to hydrogen peroxide (2 mM)-mediated oxidative insult and significantly attenuated activation of intracellular PARP-1. In anesthetized rats subjected to 30 min of coronary occlusion and 3 h of reperfusion, KR-33889 (0.3-3 mg/kg i.v.) dose-dependently reduced myocardial infarct size. KR-34285, a major metabolite of KR-33889, exerted similar patterns to the parent compound with equi- or weaker potency in the same studies described above. In separate experiments for the therapeutic time window study, KR-33889 (3 mg/kg i.v.) given at preischemia, at reperfusion or in both, in rat models also significantly reduced the myocardial infarction compared with their respective vehicle-treated group. Furthermore, the oral administration of KR-33889 (1-10 mg/kg p.o.) at 1 h before occlusion significantly reduced myocardial injury. The ability of KR-33889 to inhibit PARP in the rat model of ischemic heart was confirmed by immunohistochemical detection of poly(ADP-ribose) activation. These results indicate that the novel PARP inhibitor KR-33889 exerts its cardioprotective effect in in vitro and in vivo studies of myocardial ischemia via potent PARP inhibition and also suggest that KR-33889 could be an attractive therapeutic candidate with oral activity for several cardiovascular disorders, including myocardial infarction.


Subject(s)
Benzimidazoles/pharmacology , Cardiotonic Agents/therapeutic use , Cell Death/drug effects , Myocardial Infarction/drug therapy , Myocardial Ischemia/prevention & control , Phenylacetates/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors , Administration, Oral , Animals , Benzimidazoles/chemistry , Benzimidazoles/therapeutic use , Cell Line , Enzyme Activation/drug effects , Hydrogen Peroxide/pharmacology , Male , Mitochondria, Heart/drug effects , Mitochondria, Heart/physiology , Myocardial Infarction/prevention & control , Myocardial Ischemia/physiopathology , Myocardial Ischemia/therapy , Myocardial Reperfusion , Phenylacetates/therapeutic use , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Rats , Rats, Sprague-Dawley
17.
Biol Pharm Bull ; 31(11): 2090-6, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18981579

ABSTRACT

The present study was performed to evaluate the cardiovascular effects of ethanolic extract from the root bark of Ulmus macrocarpa (RBUM) in rats. The effects of RBUM on the vascular response of isolated rat aorta and the blood pressure of spontaneously hypertensive rats (SHRs) were evaluated. In addition, its antioxidant activity in H9c2 cells was investigated. In the free radical scavenging assay using 1,1-diphenyl-2-picrylhydrazyl stable free radical (DPPH), RBUM exhibited significant scavenging activity with an EC50 value of 14.3 microg/ml. RBUM also induced resistance to hydrogen peroxide-mediated oxidative insult in H9c2 myocardial cells. In isolated rat aortic preparations, RBUM exhibited potent vascular relaxant effect with an EC50 value of 1.9 microg/ml. This relaxation was significantly inhibited by denudation of the endothelial layer, pretreatment with NG-nitro-L-arginine methyl ester (10 microM), raising extracellular K+ (45 mM), and pretreatment with tetraethylammonium (10 mM). In an antihypertensive study with SHRs, long-term administration with RBUM (100 mg/kg) for 42 d decreased systolic blood pressure (approximately 20 mmHg). In SHRs after 42 d of treatment, RBUM recovered aortic relaxation to acetylcholine and sodium nitroprusside, and attenuated lipid peroxidation in liver of SHRs. These results suggest that chronic treatment with RBUM exerts antihypertensive effects in SHRs, and its direct vasorelaxant and antioxidant properties may contribute to reduce elevated blood pressure.


Subject(s)
Free Radical Scavengers/therapeutic use , Hypertension/drug therapy , Ulmus/chemistry , Vasodilation/drug effects , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Aorta, Thoracic/physiopathology , Blood Pressure/drug effects , Cell Line , Comet Assay , DNA Damage , Dose-Response Relationship, Drug , Free Radical Scavengers/isolation & purification , Free Radical Scavengers/pharmacology , Heart Rate/drug effects , Hypertension/metabolism , Hypertension/physiopathology , Lipid Peroxides/metabolism , Liver/drug effects , Liver/metabolism , Male , Oxidants/pharmacology , Plant Bark/chemistry , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Plant Roots/chemistry , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Rats, Sprague-Dawley , Vasoconstrictor Agents/pharmacology
18.
Arch Pharm Res ; 31(4): 482-9, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18449506

ABSTRACT

The cardioprotective effects of KR-31762, a newly synthesized K+(ATP) opener, were evaluated in rat models of ischemia/reperfusion (I/R) heart injury. In isolated rat hearts subjected to 30-min global ischemia followed by 30-min reperfusion, KR-31762 (3 and 10 microM) significantly increased the left ventricular developed pressure (LVDP) and double product (heart rate x LVDP) after 30-min reperfusion in a concentration-dependent manner, while decreasing the left ventricular end-diastolic pressure (LVEDP). KR-31762 also significantly increased the time to contracture (TTC) during ischemic period (20.0, 22.4 and 26.4 min for control, 3 and 10 microM, respectively), while decreasing the release of lactate dehydrogenase (LDH) from the heart during 30 min reperfusion (30.4, 14.3 and 19.7 U/g heart weight, respectively). All these parameters except LDH release were reversed by glyburide (1 microM), a nonselective blocker of K+(ATP) channel, but not by 5-hydroxydecanoate, a selective blocker of mitoK+(ATP) channel. In anesthetized rats subjected to 45-min occlusion of left anterior descending coronary artery followed by 90-min reperfusion, KR-31762 significantly decreased the infarct size (60.8, 40.5 and 37.8% for control, 0.3 and 1.0 mg/kg, iv, respectively). KR-31762 slightly relaxed the isolated rat aorta precontracted with methoxamine (IC(50): 23.5 microM). These results suggest that KR-31762 exerts potent cardioprotective effects through the opening of sarcolemmal K(ATP) channel in rat hearts with the minimal vasorelaxant effects.


Subject(s)
Benzopyrans/pharmacology , Cardiotonic Agents/pharmacology , Indoles/pharmacology , KATP Channels/agonists , Membrane Transport Modulators/pharmacology , Myocardial Infarction/prevention & control , Myocardial Reperfusion Injury/prevention & control , Myocardium/metabolism , Sarcolemma/drug effects , Ventricular Function, Left/drug effects , Animals , Aorta/drug effects , Benzopyrans/therapeutic use , Cardiotonic Agents/therapeutic use , Decanoic Acids/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Glyburide/pharmacology , Guanidines/pharmacology , Heart Rate/drug effects , Hydroxy Acids/pharmacology , Indoles/therapeutic use , KATP Channels/metabolism , L-Lactate Dehydrogenase/metabolism , Male , Membrane Transport Modulators/therapeutic use , Methoxamine/pharmacology , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocardial Reperfusion Injury/physiopathology , Myocardium/enzymology , Myocardium/pathology , Potassium Channel Blockers/pharmacology , Rats , Rats, Sprague-Dawley , Sarcolemma/metabolism , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , Ventricular Pressure/drug effects
19.
Planta Med ; 74(3): 233-8, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18283615

ABSTRACT

Saururus chinensis has been widely used as a traditional medicine for the treatment of beriberi, hypertension, pneumonia, edema, jaundice and gonorrhea. However, there is only limited information on the cardiovascular effects of S. chinensis extract or its single compounds. The present study was performed to investigate the effects of active lignans isolated from the extract of S. chinensis on vascular responses and heart functions. The vasorelaxant activity-guided fractionation of roots extract of S. chinensis led to the isolation of eight lignans as active principles. These lignans produced concentration-dependent relaxations of the endothelium-intact aortic preparations of rat aorta. Particularly, saucerneol ( 1), saucerneol D ( 2) and machilin D ( 8) exhibited distinctive vasorelaxant activity (EC (50) values: 2.2, 12.7 and 17.8 microM, respectively), which were significantly inhibited by removal of functional endothelium or pretreatment with N(G)-nitro-L-arginine methyl ester. Saucerneol ( 1) and saucerneol D ( 2) caused a significant decrease in left ventricular pressure, +dP/dt (max) and heart rate in isolated hearts. These results suggest that several lignans including saucerneol ( 1), saucerneol D ( 2) and machilin D ( 8), isolated from the ethanol extract of the roots of S. chinensis, have significant cardiovascular effects such as vasorelaxant and negative inotropic actions.


Subject(s)
Heart/drug effects , Lignans/pharmacology , Saururaceae/chemistry , Vasodilation/drug effects , Animals , In Vitro Techniques , Lignans/isolation & purification , Male , Radioligand Assay , Rats , Rats, Sprague-Dawley
20.
Fundam Clin Pharmacol ; 21(3): 255-63, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17521294

ABSTRACT

The present study was performed to evaluate the cardioprotective effects of KR-33028, a novel Na+/H+ exchanger subtype 1 (NHE-1) inhibitor, in rat and dog models of coronary artery occlusion and reperfusion. In anesthetized rats subjected to a 45-min coronary occlusion and a 90-min reperfusion, KR-33028 at 5 min before occlusion (i.v. bolus) dose-dependently reduced myocardial infarct size from 58.0% to 46.6%, 40.3%, 39.7%, 33.1%, and 27.8% for 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg respectively (P < 0.05). In anesthetized beagle dogs that underwent a 1.0-h occlusion followed by a 3.0-h reperfusion, KR-33028 (3 mg/kg, i.v. bolus) markedly decreased infarct size from 45.6% in vehicle-treated group to 16.4% (P < 0.05), and reduced the reperfusion-induced release in creatine kinase myocardial band isoenzyme (MB), lactate dehydrogenase, troponin-I, glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase. In separate experiments to assess the effects of timing of treatment, KR-33028 (1 mg/kg, i.v. bolus) given 10 min before or at reperfusion in rat models also significantly reduced the myocardial infarct size (46.3% and 44.1% respectively) compared with vehicle-treated group. In all studies, KR-33028 caused no significant changes in any hemodynamic profiles. In an isolated rat heart model of hypothermic cardioplegia, KR-33028 (30 mum), which was added to the heart preservation solution (histidin-tryptophan-ketoglutarate) during hypothermic cardioplegic arrest, significantly improved the recovery of left ventricular developed pressure, heart rate and dP/dt(max) after reperfusion. Taken together, these results indicate that KR-33028 significantly reduced the myocardial infarction induced by ischemia and reperfusion in rats and dogs, without affecting hemodynamic profiles.


Subject(s)
Cardiotonic Agents/pharmacology , Guanidines/pharmacology , Myocardial Infarction/drug therapy , Myocardial Reperfusion Injury/drug therapy , Sodium-Hydrogen Exchangers/antagonists & inhibitors , Thiophenes/pharmacology , Alanine Transaminase/metabolism , Animals , Aspartate Aminotransferases/metabolism , Blood Pressure/drug effects , Creatine Kinase/metabolism , Dogs , Heart Rate/drug effects , L-Lactate Dehydrogenase/metabolism , Male , Myocardial Infarction/metabolism , Myocardial Infarction/physiopathology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/physiopathology , Rats , Rats, Sprague-Dawley , Troponin I/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...